γ-Tocotrienol inhibits HeLa cell proliferation likely via modulation of the PI3K/AKT/mTOR signaling pathway

Area of Science:

• Oncology
• Molecular Biology
• Nutritional Science

Background:

• Gamma-tocotrienol (γ-T3), a natural vitamin E isoform, exhibits anticancer properties.
• The precise molecular mechanisms underlying γ-T3's anticancer activity require further elucidation.
• The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is frequently dysregulated in cancer.

Purpose of the Study:

• To investigate the effect of γ-T3 on human cervical cancer HeLa cell growth.
• To determine if γ-T3 modulates the PI3K/AKT/mTOR signaling pathway in HeLa cells.
• To assess the impact of γ-T3 on cell proliferation, cell cycle, and apoptosis.

Main Methods:

• HeLa cells were treated with varying concentrations of γ-T3.
• Protein expression and phosphorylation of PI3K, AKT, mTOR, and downstream targets were analyzed.
• Cell proliferation, cell cycle distribution, and apoptosis were assessed; wortmannin (WM) was used as a comparator.

Main Results:

• γ-T3 significantly reduced PI3K, AKT, and mTOR expression and phosphorylation, along with downstream effectors p70S6K and 4E-BP1.
• γ-T3 suppressed proliferation-associated proteins cyclin D1 and c-Myc, inhibited cell proliferation, induced G0/G1 phase arrest, and promoted apoptosis.
• Combined treatment with γ-T3 and the PI3K inhibitor WM showed enhanced growth inhibition and apoptosis.

Conclusions:

• γ-T3 inhibits HeLa cell proliferation, partly through the suppression of the PI3K/AKT/mTOR signaling pathway.
• These findings highlight γ-T3's potential as a nutrition-relevant bioactive compound for cancer prevention.
• γ-T3 may serve as a potential adjunct to conventional cancer therapies.